Novo Ventures is ready for steady deployment of funds amid IPO lull
Novo Ventures senior partner, Naveed Siddiqi, discussed the opportunity in a slumbering IPO market to raise larger funding rounds, in an interview with Unquote.
Tag Archive for: Novo Holdings
How Early-stage VCs are Adjusting in a Bear Market
As part of a panel session, hosted by Stephen Hansen, at the Anglonordic Life Science conference on 5 May, Optimum’s clients explored the latest dynamics of syndicate building for early-stage VCs.
Engimmune Therapeutics raises CHF 15.5 million in seed financing to develop novel T-cell receptor therapeutics
Financing co-led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch Proceeds will be used to develop next-generation T-cell receptor-based therapies for cancer treatment TCR therapy pioneer and industry veteran Dr Bent Jakobsen appointed as Chairman of the Board Basel, Switzerland, May 3, 2022. Engimmune Therapeutics AG (“Engimmune”), a Swiss biotech company developing novel […]
Novo Holdings Portfolio Company ReViral to be Acquired by Pfizer
Deal value of up to US$525 million Novo Holdings co-led ReViral Series B financing in 2018 ReViral developing novel antiviral therapies to treat RSV infections Validation of Novo Holdings’ strategy to identify and invest in high quality European biotech opportunities Copenhagen, Denmark – Novo Holdings A/S, a leading international life sciences investor, today announces that its […]
Novo Nordisk Foundation, Open Philanthropy, and Bill & Melinda Gates Foundation Launch Initiative to Support New Antiviral Medicines for Future Pandemics
COPENHAGEN – SAN FRANCISCO – SEATTLE. Today, the Novo Nordisk Foundation, Open Philanthropy, and the Bill & Melinda Gates Foundation announced an initial commitment of up to $90 million of coordinated funding toward Pandemic Antiviral Discovery (PAD), a new initiative to catalyze discovery and early development of antiviral medicines for future pandemics. With equitable access […]
